Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $16.13 and last traded at $16.14, with a volume of 740838 shares changing hands. The stock had previously closed at $17.94.
Analysts Set New Price Targets
SYRE has been the subject of a number of research analyst reports. Wolfe Research assumed coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, Wedbush reiterated an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $50.33.
Check Out Our Latest Analysis on SYRE
Spyre Therapeutics Trading Down 8.6 %
The stock has a market capitalization of $770.69 million, a PE ratio of -1.71 and a beta of 3.05. The business's 50 day moving average is $19.85 and its 200 day moving average is $25.08.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08. As a group, analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of SYRE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Spyre Therapeutics by 4.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,741 shares of the company's stock worth $527,000 after buying an additional 916 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Spyre Therapeutics during the 4th quarter worth about $29,000. MetLife Investment Management LLC grew its holdings in Spyre Therapeutics by 6.2% during the 4th quarter. MetLife Investment Management LLC now owns 21,382 shares of the company's stock worth $498,000 after acquiring an additional 1,250 shares in the last quarter. Huntington National Bank purchased a new position in Spyre Therapeutics during the 4th quarter valued at about $34,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Spyre Therapeutics in the 4th quarter valued at about $46,000. Institutional investors own 80.39% of the company's stock.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Articles
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
